GeneTex
  • Country / Location Selection

United States (US)
SARS-CoV-2 (COVID-19)

SARS-CoV-2 (COVID-19)

SARS-CoV-2 (COVID-19) antibodies

 

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019 Novel Coronavirus (2019-nCoV), is a positive-sense, single-stranded RNA virus that causes the potentially lethal COVID-19 respiratory tract infection. This new virus belongs to the genus Betacoronavirus, which also includes SARS-CoV and MERS-CoV.

GeneTex is proud to offer an extensive line of research antibodies and proteins to support the study of SARS-CoV-2, several of which were validated using virus-infected cell lysates. Please see the highlighted products below or click the button to see more product information.

See Product List

 

Highlighted Products
Citation Support  Protein Overexpression Recombinant

 

Antibodies

SARS-CoV-2 (COVID-19) Spike S1 antibody [HL6]

Spike antibody [1A9] (GTX632604)

Citation Support Protein Overexpression

 

SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604)

Spike S1 antibody [HL6] (EC50: 0.552 nM) (GTX635654)

Recombinant Antibody

 

SARS-CoV-2 (COVID-19) nucleocapsid antibody [HL249]

Spike RBD antibody [HL257] (GTX635692)

Recombinant Antibody
SARS-CoV-2 (COVID-19) nucleocapsid antibody

Nucleocapsid antibody [HL5511] (EC50: 0.014 nM) (GTX635689)

ACE2 antibody [N1N2], N-term (GTX101395)

PLpro (nsp3) antibody (GTX135589)

TMPRSS2 antibody [N2C3] (GTX100743)

RdRp (nsp12) antibody (GTX135467)

Proteins

SARS-CoV-2 (COVID-19) nucleocapsid protein, His tag

Spike S1 protein, His and Avi tag (active) (GTX01548-pro)

 

SARS-CoV-2 (COVID-19) Spike S1 protein, His and Avi tag (active)

Spike RBD protein, His tag (active)

(GTX01546-pro)

 

SARS-CoV-2 (COVID-19) Spike RBD protein, His tag (active)

Nucleocapsid protein, His tag (GTX135592-pro)

ELISA Pairs

SARS-CoV-2 (COVID-19) nucleocapsid protein, His tag

Nucleocapsid ELISA Pair [HL5511 / HL448] (GTX500045)

 

SARS-CoV-2 (COVID-19) Spike S1 protein, His and Avi tag (active)

Nucleocapsid ELISA Pair [HL5410 / HL455-MS] (GTX500042)

 

SARS-CoV-2 (COVID-19) Spike RBD protein, His tag (active)

Spike ELISA Pair [1A9 / HL6] (GTX500040)

 

The first case of COVID-19 was detected in December, 2019 in Wuhan, China, and has now been declared a pandemic (1). With SARS-CoV-2 now reaching pandemic status, researchers and clinicians have been working furiously to learn more about the virus’s biology and pathogenesis as well as how to treat the more clinically aggressive COVID-19 cases.

In their study published very recently in Cell, Hoffmann et al. confirm findings reported by Zhou et al. that angiotensin-converting enzyme 2 (ACE2) is the cellular receptor for SARS-CoV-2, as it is for SARS-CoV (2, 3). In addition, they identify the serine protease TMPRSS2 as a critical factor in the priming of the SARS-CoV-2 spike (S) protein, an essential step for viral entry into host cells through fusion of the viral and cellular membranes. The authors also demonstrate that the serine protease inhibitor camostat mesylate, an agent that has already seen clinical application as a treatment for chronic pancreatitis in Japan, is able to interfere with SARS-CoV-2 infection of lung cells.

 

SARS-CoV-2 (COVID-19) antibodies
Adapted from Science 367(6485), 1412-1413 (2020).

 

To further expedite the identification of agents with activity against SARS-CoV-2, the WHO’s SOLIDARITY study will assess the potential utility of four different classes of clinically known drugs or drug combinations against the virus (4). The four arms include the viral polymerase inhibitor remdesivir, the anti-malarial agents chloroquine and hydroxychloroquine, the HIV protease inhibitors lopinavir and ritonavir, and lopinavir/ritonavir with interferon-beta. This study, which is one of many ongoing trials that are reviewing more than a dozen possible therapies, is stripped down to accelerate data acquisition and be accessible to physicians everywhere. The central focus of many of these trials is to evaluate existing agents with acceptable safety profiles (e.g., the serine protease inhibitor camostat mesylate) that are amenable to repurposing for use against SARS-CoV-2. In addition, compounds previously found to have activity against SARS-CoV, MERS-CoV, or other viruses are being reexamined, as is the use of convalescent plasma from recovered COVID-19 patients and monoclonal antibodies targeting viral components (5). The singular determination to fight this virus as a world community is now widely appreciated as the only path to eventual success.

 

References:

  1. Nature News. 11 March 2020.
  2. Nature 579, 270-273 (2020).
  3. Cell 181, 1-10 (2020).
  4. Science 367(6485), 1412-1413 (2020).
  5. Science 2020 Apr 3. pii: eabb7269.
Newsletter

Neuropilins Facilitate SARS-CoV-2 Entry into Host Cells

Neuropilins Facilitate SARS-CoV-2 Entry into Host Cells
Literature
Pamphlet - SARS-CoV-2 (COVID-19) Research Reagents

Pamphlet - SARS-CoV-2 (COVID-19) Research Reagents

SARS-CoV-2 (COVID-19) Research Reagents
Newsletter

Zika Virus Infection Increases Risk of Subsequent Severe Dengue Disease

Zika Virus Infection Increases Risk of Subsequent Severe Dengue Disease
Promotion
Now buy a standard-size primary antibody and get a 25 ul size FREE!

Buy 1 get 1 free!

Now buy a standard-size primary antibody and get a 25 ul size FREE!
Newsletter
GeneTex SARS-CoV-2 (COVID-19) Nucleocapsid Protein Sandwich ELISA Kit

GeneTex SARS-CoV-2 (COVID-19) Nucleocapsid Protein Sandwich ELISA Kit

This kit allows highly specific, ultrasensitive detection of SARS-CoV-2 N protein with an average lowest detection limit of 18 pg/ml.
Literature
Brochure - SARS-CoV-2 (COVID-19) Research

Brochure - SARS-CoV-2 (COVID-19) Research

Download the latest version of GeneTex's SARS-CoV-2 (COVID-19) Research brochure.
Newsletter
IHC- and FCM-validated Antibodies for SARS-CoV-2 Research

IHC- and FCM-validated Antibodies for SARS-CoV-2 Research

IHC- and FCM-validated Antibodies for SARS-CoV-2 Research
Newsletter
Spike Antibody-mediated Neutralization of SARS-CoV-2

Spike Antibody-mediated Neutralization of SARS-CoV-2

Spike Antibody-mediated Neutralization of SARS-CoV-2
Newsletter
Profiling cytokine storm in COVID-19 patients by metatranscriptomic sequencing

Profiling cytokine storm in COVID-19 patients by metatranscriptomic sequencing

Profiling cytokine storm in COVID-19 patients by metatranscriptomic sequencing
Articles
A Review of the SARS-CoV-2 (COVID-19) Genome and Proteome

A Review of the SARS-CoV-2 (COVID-19) Genome and Proteome

GeneTex is proud to offer an extensive line of reagents to support the study of SARS-CoV-2 / COVID-19.
Articles
SARS-CoV-2 Webinar: A World Problem Needing a World Response

GeneTex Webinar: SARS-CoV-2 and COVID-19

A World Problem Needing a World Response
Articles

The concept of a SARS-CoV-2 / COVID-19 rapid test

A rapid virus antigen test detects SARS-CoV-2 particles in samples by capturing viral antigen between a free labeled antibody and a fixed second antibody that each recognize different regions of the antigen.
Literature
SARS-CoV-2 (COVID-19) poster

Poster - SARS-CoV-2 (COVID-19)

Download the latest version of GeneTex's SARS-CoV-2 (COVID-19) poster
Newsletter

SETD3 Is Pivotal for Infection by Multiple Human Enteroviruses

In an exciting example of this concept, Diep et al. described the use of a genome-scale CRISPR screen to show that the protein histidine methyltransferase SETD3 is crucial for the replication of multiple human enteroviruses.
Literature
Pamphlet - SARS-CoV-2 (COVID-19) Research Reagents

Pamphlet - SARS-CoV-2 (COVID-19) Research Reagents

SARS-CoV-2 (COVID-19) Research Reagents
Literature
Brochure - SARS-CoV-2 (COVID-19) Research

Brochure - SARS-CoV-2 (COVID-19) Research

Download the latest version of GeneTex's SARS-CoV-2 (COVID-19) Research brochure.
Literature
SARS-CoV-2 (COVID-19) poster

Poster - SARS-CoV-2 (COVID-19)

Download the latest version of GeneTex's SARS-CoV-2 (COVID-19) poster